Hematology/Oncology

Top Story

VIDEO: Questions remain regarding use of gene-targeted therapy for lung cancer

June 23, 2017

CHICAGO — Suresh S. Ramalingam, MD, deputy director of Winship Cancer Institute of Emory University, discusses the results of a phase 3 trial that demonstrated that gefitinib prolonged DFS compared with standard-of-care chemotherapy in patients with EGFR–positive stage II or IIIa non–small cell lung cancer.

10 updates in immunotherapy research

June 23, 2017
In recognition of Cancer Immunotherapy Month, Cancer Research Institute has organized a series of educational and social events designed to raise awareness regarding…
FDA News

FDA approves BevyxXa for prevention of venous thromboembolism

June 23, 2017
The FDA granted approval to betrixaban for the prevention of venous thromboembolism and pulmonary embolism in acutely ill patients who are not undergoing surgery…
In the Journals Plus

Midostaurin extends survival in acute myeloid leukemia with FLT3 mutation

June 23, 2017
The addition of midostaurin to standard chemotherapy improved OS and EFS among patients with acute myeloid leukemia and FLT3 mutation, according to results of the RATIFY…

High-dose vitamin C may increase efficacy of cancer therapies

June 23, 2017
The addition of high-dose vitamin C to standard chemotherapy or radiation appeared to effective and safe for patients with glioblastoma multiforme and non–small…
More News Headlines »
CME

Bridging the Gap from Knowledge to Practice in CRPC

This activity is supported by educational funding provided by AbbVie Inc.; Astellas Scientific and Medical Affairs, Inc. and Medivation; and Sanofi US.

The selection of therapy for patients with castration-resistant prostate cancer (CRPC) remains challenging. Review…
More »
Video
Meeting News

VIDEO: Pembrolizumab may improve response to CAR T-cell therapy in children with ALL

June 20, 2017
More »
Featured
ASCO Annual Meeting

ASCO Annual Meeting

CME

What's Hot in Melanoma? Highlights from the HemOnc Today Melanoma and Cutaneous Malignancies 2017 Meeting

This activity is supported by an educational grant from Merck & Co, Inc.

The development and integration of targeted therapies, as well as immunotherapies, into clinical strategies for the…
More »
Current Issues
View the Current Issue
HemOnc Today
Advertisement
Advertisement